Positron emission tomography studies with fluorodeoxyglucose in patients with schizophrenia are reviewed and findings in the frontal lobes, basal ganglia, and temporal lobes summarized from more than 20 published studies. Despite methodological and clinical population differences between studies, most reports indicate that patients with schizophrenia are more likely to be low in these areas than in the. occipital lobe, cerebellum, or in white matter. This is consistent with blood flow and some neuroanatomical findings. Ouster analysis on our own sample suggests that patients may be low in all three areas rather than a pattern of three distinct dusters. Further study of individual symptom differences, medication effects, and of psychophysical tasks salient for these brain areas is indicated.
Three brain areas are the current scientific targets in schizophrenia research: the frontal lobes, the basal ganglia, and the temporal lobes, especially the hippocampus. Reduced frontal lobe function, supported by blood flow, positron emission tomographic (PET) and electroencephalographic (EEG) studies, is consistent with behavioral deficits in executive functions in schizophrenia, but less directly compatible with information about the distribution of dopamine receptors and medication effects. Basal ganglia dysfunction is consistent with the dopamine hypothesis, some autopsy and PET studies of receptor density, and with neuroleptic response, but less easily related to the symptoms of thought disorder, hallucinations, and social withdrawal. Temporal lobe dysfunction is supported by magnetic resonance imaging (MRI) studies, some computed tomographic (CT) studies, and EEG studies, and is consistent with sensory and verbal symptoms but less closely linked to dopamine receptor change.
Are there three distinct types of schizophrenia-frontal, basal ganglia, and temporal lobe illnesswith possibly differing etiology, course, and response to treatment? Or are there varying degrees of a deficit in a single frontal-striataltemporal neural system? Few studies have provided functional assessments of all three brain areas in a sample of sufficient size to examine biologically based subgroups and medication response. PET studies using fluorodeoxyglucose (FDG) as a tracer of metabolic rate provide a method to evaluate the activity of all three areas simultaneously, in life, in the behaving patient. With PET technology, data from all three brain areas are unavoidably available in most cases, making a systematic survey easier than with neuroanatomical methods, which increase the labor with each additional area, and EEG and xenon blood flow studies, which assess only the lateral cortex.
Frontal Lobes
The first research in PET has focused on the frontal lobes, because cerebral blood flow studies a decade ago found patients to have diminished flow in this area, and because this area is known to be important in attention, motivation, and the planning and organizing of behavior. When David Ingvar visited the National Institute of Mental Health in Bethesda in 1980, we decided to replicate his 1974 blood flow studies (Ingvar and Franzen 1974) with FDG and PET, using a small series of patients resting with their eyes closed. This series (Buchsbaum et al. 1982) revealed, like the 1974 data, a relatively diminished frontal/ occipital ratio in patients with schizophrenia (1.14 in normals, 1.05 in patients) closely comparable to the original blood flow data. Similar findings emerged when patients were receiving brief electric shocks to their right forearms (Buchsbaum et al. 1984a ) and when they were performing the Continuous Performance Test (CPT) as illustrated in figure 1 ). Our three and nine other PET studies of schizophrenia are reviewed in table 1. This summary attempts to present comparable numbers from each study, although significant differences in methodology exist.
Replication of Previous Studies.
The majority of PET and regional cerebral blood flow reports show relatively low function in the frontal regions of patients with schizophrenia. Our current (1990) data match our earlier (1982, 1984a ) studies in revealing a difference in anteroposterior gradient tested by analysis of variance (ANO\A), and a difference in frontal/occipital ratios tested by t test. We have compared studies this way to match the initial Ingvar and Franzen (1974) frontal/ occipital ratio results, to facilitate cross-study comparison, and to provide evidence for a specific regional pattern rather than global brain metabolic change. Table 1 summarizes the right frontal/occipital and frontal/whole slice data in 17 studies. We calculated the ratios from the raw data in the authors' tables or figures if data were not supplied. In some cases, only one of the ratios could be calculated from the published data. This summary revealed lower frontal to occipital ratios in 12 of 16 studies. The ratios were significantly lower in schizophrenic patients than in normal control subjects in five studies (Buchsbaum et al. 1982 (Buchsbaum et al. , 1984a Farkas et al. 1984; Wolkin et al. 1988 ) and nonsignificantly or not tested lower ratios in another six studies (Sheppard et al. 1983; Jernigan et al. 1985; Wolkin et al. 1985; Ming et al. 1986; Kishimoto et al. 1987; \folkow et al. 1987) . Two studies of the 17 (Szechtman et al. 1988; Cleghorn et al. 1989) found significantly higher ratios in patients with schizophrenia, and one study showed a tie (GUT et al. 1987a ). found significantly lower frontal metabolism in schizophrenic patients by ANOVA but did not present data from which ratios could be calculated. Early et al. (1987) did not present data in tabular form or sufficient detail to allow inclusion of the frontal/occipital ratio.
The ratio of frontal to occipital metabolic rate depends both on the frontal and occipital lobes; high occipital values can contribute to hypofrontality. This may be more powerful for characterizing a pattern of brain organization involving a • relationship between the executive functions in the frontal lobes and sensory processing in the occipital lobes. Indeed, in an oversimplified model, the pattern of hypofrontal and hyperoccipital function matches the deficits in planning and organization and the excessive sensory elaboration seen in schizophrenia. However, an alternative metric based on frontal to whole brain or whole slice metabolic rate may be useful. This method reveals relative changes in metabolic patterns, is less sensitive to methodological differences between centers than absolute metabolic rate in micromoles, and is less affected by occipital metabolism.
In our review, six studies found significantly lower ratios in schizophrenic patients (Buchsbaum et al. 1982 (Buchsbaum et al. , 1984a Wolkin et al. 1985; Kling et al. 1986; and four others found lower ratios which were not tested statistically or were nonsignificant (Farkas et al. 1984; Jernigan et al. 1985; Gur et al. 1987a; \blkow et al. 1987) . Wiesel et al. (1985) found higher ratios for areas 6 and 8 but lower ratios for areas 9 and 10. Szechtman et al. (1988) found significantly higher ratios. Sheppard et al. (1983) , Kishimoto et al. (1987) , and Early et al. (1987) did not present data making this computation possible.
In the Genain quadruplets, identical quadruplets concordant for schizophrenia, all four were 1 standard deviation below normal for the frontal/whole slice ratio and two were 2 standard deviations below normal (Buchsbaum et al. 1984b) . Their within-group variance was 0.036, which is not smaller than in our 1982 control group (n -7) or our 1984a group (n -19) with a standard deviation of 0.084 (F -2.33; df -3,18; p -0.11). Thus, while suggestive, the findings in our small sample cannot confirm a significant familial effect.
Frontal lobe metabolic rates in micromoles or mg/unit time provide a third alternative for evaluating hypofrontality. While not correcting for the wide individual differences in whole brain metabolic rate, they Wiesel et al. 1987 [areas 9 and 10 but not areas 6 and 8]; ). Only Buchsbaum et al. (1984a) found nonsignificantly higher frontal metabolic rates, perhaps because of the use of painful somatosensory stimulation, which may activate the frontal lobes. Whole brain or whole cortical metabolic rates did not differ significantly between normal subjects and schizophrenic patients in seven studies, suggesting a specific frontal lobe hypofunction and consistent with the majority of the ratio studies (Buchsbaum et al. 1984a Farkas et al. 1984; \blkow et al. 1987 [39.7 vs. 35 .9, our t test: t -1.61, p = NS]; Wiesel et al. 1987; deghorn et al. 1989) . However, the data of Gur et al. (1987a) did show significant whole cortical reductions in schizophrenic patients.
Despite the fact that these studies differ widely in uptake conditions, region of interest location and size, medication status of patients, demographic features, and sample size, a modest consistency appears.
•Variation between studies may also relate to the high levels of type n statistical error inherent in these small samples. Nevertheless, the PET data are consistent with the data showing reduced frontal cerebral blood flow (see Buchsbaum and Haier 1987) , the formulations of Ingvar (19»), Levin (1984) , , and Weinberger and Berman (1988) on the role of the frontal cortex in schizophrenia, and with the heterogeneity of schizophrenic diathesis (Buchsbaum and Rieder 1979) .
Basal Ganglia in Schizophrenia
Changes in the metabolic rate of the caudate and putamen would be consistent with the dopamine hypothesis, with autopsy changes in receptor density, and with the regional effects of neuroleptics. Figure 2 illustrates the basal ganglia in 14 off-medication schizophrenic patients and 14 normal control subjects. Table 2 reviews recent studies of metabolic rate in the basal ganglia. Of the six studies that report absolute metabolic rate, five show lower rates in patients with schizophrenia, with three being statistically significant. Nine studies either reported relative metabolic rates or the rates could be calculated from tables. These studies are relatively evenly divided between results indicating patients higher and lower than controls. Recency of neuroleptic treatment, duration of previous pharmacotherapy, and patient age may be important variables in determining metabolic rate or relative metabolic rate in this region. In our most recent group of subjects, 18 never-medicated schizophrenic patients, the basal ganglia show significantly lower relative and absolute metabolic rates. Thus, previous exposure to neuroleptics, which affect the basal ganglia metabolic rate as described below, may obscure the changes during the natural course of the illness. Asymmetry in function must also be considered. Our finding of greater relative reduction on the right and greater neuroleptic effect on the right ) is not inconsistent with the increased relative flow on the left reported by Early et al. (1987) .
The studies in table 2 also used different methods of identifying the basal ganglia region of interest. Small boxes placed stereotaxically in the center of the caudate may yield systematically higher metabolic rates than regions of interest outlined on CT or from visual placement of a region of interest "box." Shrinkage of the basal ganglia as a result of aging, chronic neuroleptic treatment, or the schizophrenic process might affect small, centrally located, stereotaxically placed boxes less than these measurement techniques. Relative metabolic rates have advantages in detecting regional changes in metabolism with sensory stimulation or cognitive task (e.g., Fox and Mintun 1989) but may be altered by shifts in cortical metabolic rate. Thus, cognitive tasks affecting large areas of the cortex could have an effect on the relative metabolic rate measured for the basal ganglia. This might account for the higher variation in the relative metabolic rate studies. We found a significant increase in metabolic rate in the putamen but no statistically significant change in the anteroposterior ratio in eight schizophrenic patients scanned both on and off neuroleptics (1.06 on medication, 10.4 off medication, t = 0.34, p -NS; Buchsbaum et al. 1987) . No cortical area showed a statistically significant increase, although a trend (p < 0.10) appeared toward increased metabolic rates. (An earlier study using one additional patient who was tested in a different condition from the others was omitted from this analysis; this report [DeLisi et al. 1985 ] showed a small increase in cortical metabolism.) Further, significant correlations were found between basal ganglia metabolic change with medication and improvement on a modified version of the Brief Psychiatric Rating Scale. Cohen et al. (1988) found increases in basal ganglia metabolic rate with neuroleptics as we did, with little effect in the frontal lobes. Interestingly, neuroleptic effects appeared primarily in areas of the brain not correlated with performance on the CPT; when medicated patients were examined, larger correlation coefficients between performance and metabolic rate were observed. Increased metabolism in the lentiform nucleus with sulpiride was also found by Wik et al. (1989) . This effect was greatest in the right, just as we had observed . GUT et al. found no effect of neuroleptics on the frontal lobe, but did not show basal ganglia effects either (Gur et al. 1987b; Resnick et al. 1988 ). The frontal lobe was one of the few areas that failed to show a significant neuroleptic effect in the study of Wolkin et al. (1985) , but the increase in occipital metabolic rate produced a statistically significant decrease in the hypofrontality ratio. Wiesel et al. (1985) and Wik et al. (1989) also reported no significant effect of sulpiride treatment on the frontal lobe, Vblkow et al. (1986) found no effects of neuroleptics anywhere in the brain but had only four patients (type II error estimated at 91%). Weinberger and Berman (1988) reviewed both the PET and cerebral blood flow studies and similarly concluded that neuroleptics did not appear responsible for the hypofrontality effect. It should be noted, however, that no study administered a fixed dose of neuroleptics for a fixed interval in a placebo-controlled, random-assignment trial; all followed drug-withdrawn patients who were subsequently treated, a design that confounds order and drug treatment effects. Analysis of data from a controlled design with patients performing a task sensitive to the effects of neuroleptics is clearly needed to resolve this issue.
Effects of Neuroleptics on Basal

Left Temporal Lobe Metabolic Rate
Both anatomical and functional studies have suggested that the left temporal lobe may be affected in schizophrenia. These studies are reviewed by Crow (1990, this issue) . 
Methodological Issues
Anatomical Shrinkage. The effect of anatomical reduction in the size of the frontal lobe, basal ganglia, or temporal lobe on PET results will have to be considered. While changes in the size of the frontal lobe and basal ganglia are uncertain, decreases in the temporal lobe have been widely reported (see Rossi et al. 1989; Bogerts et al. 1990; Crow 1990, this issue) . Enlargement of the temporal horn might affect medial measurements but would be less likely to affect the lateral surface metabolic rate. Reduction in temporal lobe size is a more complicated issue. If temporal lobe size reduction were due to loss of neurons in the lateral gray matter, a reduction in metabolic rate might follow. This would depend, however, on whether the remaining cells were unchanged in activity. If a larger percentage of the cells were activated in a cognitive task, the metabolic rate per unit area or volume might remain unchanged. Loss of supporting cells could lead to a concentration of neurons and even an increased metabolic rate per unit volume. A small region of interest centered in temporal cortex thus might actually show an increase. Alternatively, a widened sulcus would include more cerebrospinal fluid in a region of interest and reduce the measured metabolic rate. Measurement of the total metabolism of the whole lobe or its constituent parts using MRI templates that separate gray and white matter may be necessary to resolve this question. It should be noted, however, that a regional metabolic decrease can still identify a dysfunctional region and cannot, strictly speaking, be considered an artifact of structural change. Moreover, small losses of key neurons may impede cognitive function greatly, and be detectable on metabolic imaging long before the change is great enough to appear on the MRI.
Asymmetry. As reviewed above, many findings in the basal ganglia and temporal lobe appear to be asymmetrical. Mere random positioning error would not create statistically significant asymmetries. However, a systematic bias in head tilt in schizophrenic patients could be related to such phenomena as body turning (Bracha 1987) ; thus, a lateralized brain disorder could erroneously appear in the wrong brain area. Zipursky et al. (1990) , in a detailed geometrical analysis, noted that head tilt produces more marked asymmetry in the area of a structure which is higher on the head; the basal ganglia, at 4-6 cm above the canthomeatal line and the temporal lobe at 2-4 cm, might be somewhat less affected by tilting effects than the top of the ventricular system. The use of firmly fitting head holders and care in head alignment are helpful in this problem.
Uncontrolled Clinical Variables.
Study populations vary widely in sex, symptom severity, and age composition. Females may have higher metabolic rates than males (Baxter et al. 1987 ). Regional differences in correlations between metabolic rate and age were reported by Jernigan et al. (1985) . We found that the anteroposterior ratio correlated -0.58 with age. While most reported studies achieved some match between patient and normal populations, the differences in metabolic rates may reflect population diversity. Subject anxiety has been suggested to be an important factor in metabolic rates, but a recent study (Giordani et al. 1990) failed to confirm earlier reports. Correlations between metabolic rate and symptoms were positive in two studies (\folkow et al. 1987; Delisi et al. 1989) , but only large sample sizes will allow control of these variables. The nonspecificity of the findings for schizophrenia is discussed elsewhere (Baxter et al. 1985; Buchsbaum et al. 1986 ). Tasks such as the CPT (Cornblatt et al. 1988 or smooth pursuit eye movements may affect PET results \blkow et al. 1988) .
Resllcing the Brain
The complex, irregular structures of the basal ganglia and temporal lobe make quantitative assessment difficult. Reconstruction in image planes other than the one in which the images were acquired may be useful to portray changes (figure 3). The block of image data can be reconstructed in new planes parallel to the main axis of the structure of interest. Figure 4 shows the original images of a PET axial series and the reconstruction into sagittal images. The sagittal plane lines in figure 5 show the positions for the three slices for a normal subject and a schizophrenic patient in figures 6 and 7. The cingulate gyrus and the medial frontal regions are more clearly displayed as a region of hypofunction in these views. Similarly, for the temporal lobe, coronal and 15°-tilted axial sections will be useful; no PET studies on schizophrenia have used this method to date.
Relationships Among the Three Brain Regions
If there were three types of schizophrenia-frontal, basal ganglia, and left temporal-one might expect to see little correlation between the three regions in a mixed population of schizophrenic patients. If schizophrenia involved a dysfunction in all three areas, then one might expect to see high correlations between the areas. For metabolic data in micromoles, the correlation coefficients among all brain regions are very high. In our current cohort of 18 never-medicated schizophrenic patients, the median correlation coefficient in a matrix of 20 structures was 0.80. Thus, a clear separation into individuals with deficits in only one region was not observed. Stepwise regression analysis predicting schizophrenia in the 18 nevermedicated patients and 20 control subjects produced a significant group separation whether frontal, basal ganglia, or left temporal metabolic rate was forced first in the regression; subsequent addition of the other two regions did not significantly increase the variance explained. We also investigated the use of hierarchical duster analysis in this population. Entering 20 normal subjects and 18 patients, we anticipated the possibility of a division into normal and patient groups and then a subdivision into three types of patients. We selected three brain areas in the frontal lobe, basal ganglia, and temporal lobe. The theoretical hierarchy did not emerge, however. Instead, we observed two groups of normal subjects and two groups of schizophrenic patients. One group of patients had low values in all three structures, and the second was low in the two cortical areas. No clinical features dearly distinguished these dusters. Review of absolute rate data in tables 1-3 is somewhat consistent with this result: a tendency for schizophrenic patients to have low metabolic rates in all three areas. As noted in the discussion of hypofrontality, however, whole brain metabolic rate rarely differentiated normal subjects from schizophrenic patients. Octipital, cerebellar, and white matter findings are rare across the PET literature. Taken together, the results of the PET studies are not inconsistent with the concept of a defect in a fronto-striatal-temporal system. The other reviews in this issue provide a wealth of data for frontal, basal ganglia, and temporal lobe dysfunction. Correlative studies, assessing all three areas in the same data base, will be important in supporting the concept of three schizophrenias or one schizophrenia with a three-region diathesis.
